CymaBay Therapeutics, Inc. (0I5P.L)
| Previous close | 21.70 |
| Open | 21.36 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 21.13 - 21.36 |
| 52-week range | 4.06 - 21.70 |
| Volume | |
| Avg. volume | 2,429 |
| Market cap | 14.039M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.32 |
| Earnings date | 07 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to five employees on November 15, 2023 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymaBay approved the grant of non-quali
PR NewswireCymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the results from its RESPONSE Phase 3 registration study evaluating seladelpar, a potent, selective, orally-active delpar, or PPAR𝛿 agonist, in adult patients with primary biliary cholangitis (PBC) will be featured as an oral presentation in today's Late Breaker Session of the American Association for the Study of Liver Di
Insider MonkeyCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q3 2023 Earnings Call Transcript
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q3 2023 Earnings Call Transcript November 7, 2023 CymaBay Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.3. Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s Third Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a […]
